Spinal Cord Stimulator Statistics (2026): Success Rates, Trials, and Outcomes Data

Spinal cord stimulator trials succeed for a large share of carefully selected patients, with reported trial success rates ranging from 50% to 75% and reaching 86.1% in one real-world study of 505 patients. But the therapy is not universal: failure rates of up to 44% and annual explantation rates of 6% to 9% make patient selection critical. Here is what the 2026 data says about how well spinal cord stimulation works, why trials matter, and who benefits most.

What's in This Guide

01 Trial Success and Response Rates

A spinal cord stimulator (SCS) delivers mild electrical pulses to the spinal cord to interrupt pain signals before they reach the brain. Unlike most procedures, it comes with a built-in test drive: a temporary trial before any permanent implant.

The headline numbers are encouraging but wide. Clinical sources commonly report SCS trial success between 50% and 75%, depending on the pain syndrome and patient factors. A real-world study of 505 patients who underwent SCS trials between 2022 and 2024 found that 86.1% achieved trial success, defined as at least 50% pain relief at the time of lead removal. That spread reflects a central truth about SCS: outcomes depend heavily on which patients are selected and how success is measured.

The trial period is what makes these numbers actionable. Because patients only proceed to a permanent implant if the trial delivers meaningful relief, the therapy has a natural filter that most interventions lack.

Source: SCS review citing PMC real-world data | SCS trial success (clinical reference)

02 Trial-to-Implant Conversion

How many patients who trial an SCS go on to a permanent device is one of the most telling metrics, because it captures real-world decision-making, not just study endpoints.

Conversion rates vary by setting. A utilization study published in the North American Spine Society Journal found 67% of SCS patients progressed from trial to permanent implant, while a 20-year single-center audit reported a 93.6% trial-to-implant ratio, 191 of 204 trialed patients went on to implantation. The gap between these figures reflects differences in patient selection and program design. Research has identified a "fantastic four" of predictors, age, stimulator waveform, pain localization, and history of spine surgery, that influence the odds of a successful trial.

Source: North American Spine Society Journal, 2025 | 20-year SCS audit (ScienceDirect)

03 Who Spinal Cord Stimulation Helps

SCS is not a general-purpose back-pain treatment. Its strongest evidence is concentrated in specific, well-defined conditions.

The leading indication is failed back surgery syndrome (FBSS), persistent or recurrent low back and leg pain after lumbar surgery, which affects an estimated 10% to 40% of patients who undergo lumbar procedures. SCS is also established for complex regional pain syndrome, chronic radicular leg pain, and diabetic peripheral neuropathy. A retrospective study found that SCS significantly improved back pain, leg pain, and overall pain at one year in both patients under 75 and those 75 and older, with no significant difference in complications between age groups, useful reassurance given the older skew of the Greater Phoenix patient population.

Source: PMC, SCS efficacy for FBSS in elderly patients | SCS review citing JAMA Network Open 2024

04 Failure, Explantation, and Realistic Expectations

An honest statistics article has to include the downside, and SCS has a real one. Balanced expectations are part of good care.

A 2025 retrospective cohort study from Saint Louis University, published in Neurology International, identified failure rates of up to 44% and annual explantation rates of 6% to 9%. Failure can result from loss of efficacy over time, lead migration, or infection, and non-rechargeable systems require periodic battery-replacement surgery every two to five years. Rare but serious adverse events, including infection requiring device removal, have been reported. The researchers framed these figures as a clear reason to identify high-risk patients before implantation rather than after.

The 2024 JAMA Network Open network meta-analysis reinforced the nuance: SCS showed advantages over conventional medical management for certain populations, but with significant variability in outcomes and a strong emphasis on careful patient selection. This is precisely why the trial period, and the expertise of the physician choosing candidates, matters so much.

Source: SCS review citing Neurology International 2025 & JAMA Network Open 2024 | North American Spine Society Journal, 2025

05 Where SCS Fits in Spine Care

Spinal cord stimulation sits near the top of the interventional ladder, considered after other options, but before or instead of further open surgery for the right patient.

Because SCS is most often used for failed back surgery syndrome, it typically enters the conversation after conservative care, interventional procedures, and, where relevant, prior surgery. The dual expertise of a physician who is both a spine surgeon and a neurosurgeon is especially relevant here: the same specialist who can evaluate whether revision surgery is warranted can also determine whether neuromodulation is the better path, without a referral handoff.

This is general information, not individual medical advice. Whether spinal cord stimulation is appropriate depends on a full evaluation and a successful trial.

Source: 20-year SCS audit for FBSS (ScienceDirect) | PMC, SCS efficacy for FBSS

06 All the Numbers in One Table

07 Frequently Asked Questions